Phase I/II Trial of Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Launched by MISTY SHIELDS ·
Trial Information
Current as of November 11, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new combination of medicines, lurbinectedin and osimertinib, to see if they are safe and helpful for treating a rare form of lung cancer called transformed small cell lung cancer (SCLC). This type of cancer can develop when lung cancer changes into a more aggressive form, and current treatment options are limited. The goal of the study is to find out if this new treatment can better control the cancer and improve patients’ health.
The trial is open to adults aged 65 to 74 of all genders who have this specific type of lung cancer. Since the study is still in the early phase and not yet recruiting participants, those who join can expect close medical monitoring to check for side effects and to see how well the treatment works. If you or a loved one fits the age range and diagnosis, you might want to talk with your doctor about this trial to learn more about the potential benefits and risks.
Gender
ALL
Eligibility criteria
About Misty Shields
Misty Shields is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on supporting high-quality, ethically conducted studies, Misty Shields collaborates with researchers and healthcare professionals to facilitate the development of safe and effective treatments. Their commitment to patient safety, scientific integrity, and regulatory compliance ensures the successful execution of clinical trials aimed at improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Misty D Shields, MD, PhD
Principal Investigator
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported